Novavax Vaccine Updates: U.S. Phase 3 Data, Efficacy Against Beta Variant

Novavax stock has gained about 12% over the last five trading days and has rallied by a solid 73% over the last month, largely recovering from the sell-off in late April and early May when the company said that it would delay seeking authorization of its Covid-19 shot to the third quarter of this...